What is the Difference Between Basaglar VS Lantus Insulin?
Basaglar vs. Lantus Insulin
Basaglar and Lantus are both insulin glargine medications. They are long-acting insulin analogues. Basaglar was approved in December 2015 and is a “follow-on” to Lantus. Basaglar is manufactured by Eli Lilly and Lantus is manufactured by Sanofi-Aventis.
What is are these medications used for?
Basaglar and Lantus are used to control blood glucose levels in adults and children 6 years old and up with type 1 diabetes and adults with type 2 diabetes.
How to take
Basaglar and Lantus insulin are both meant to be injected subcutaneously. They should be injected once a day, ideally at the same time every day. They should not be combined with other insulins and should not be administered via an insulin pump. Basaglar and Lantus should not be injected into muscles or veins.
Basaglar and Lantus insulin are safe and approved medications. However, some adverse effects may still occur.
Common side effects
- Sore throat
- Runny or stuffy nose
Severe side effects
- Indentation of the skin at the injection site
- Pain, redness, swelling, or itching at the injection site
- Thickening of the skin at the injection site
Basaglar and Lantus contain 100 units of insulin per 1 mL of the medication. The dosage of each of these insulin products may need to be adjusted based on the patient’s blood glucose levels, glycemic control goal, and metabolic needs. The typical dosage when patients begin treatment with Basaglar or Lantus insulin is up to 10 units injected once daily.
Disclaimer: Please note that the contents of this community article are strictly for informational purposes and should not be considered as medical advice. This article, and other community articles, are not written or reviewed for medical validity by Canadian Insulin or its staff. All views and opinions expressed by the contributing authors are not endorsed by Canadian Insulin. Always consult a medical professional for medical advice, diagnosis, and treatment.